SPECTRUM CHEMICAL MFG. CORP. -- PROGESTERONE  -- -
<pre>=====================  Product Identification  =====================

Product ID:PROGESTERONE
MSDS Date:09/16/1991
FSC:NIIN:Submitter:N EN
Status Code:A
=== Responsible Party ===
Company Name:SPECTRUM CHEMICAL MFG. CORP.
Address:14422 SOUTH SAN PEDRO STREEET
City:GARDENA
State:CA
ZIP:90248-2027
Country:US
Info Phone Num:310-516-8000
Emergency Phone Num:(800)424-9300
Chemtrec Ind/Phone:(800)424-9300
CAGE:63415
=== Contractor Identification ===
Company Name:SPECTRUM LABORATORY PRODUCTS INC
Address:14422 S SAN PEDRO ST
Box:City:GARDENA
State:CA
ZIP:90248-2027
Country:US
Phone:310-516-8000/FAX: 310-516-9843
CAGE:63415

=============  Composition/Information on Ingredients  =============

Ingred Name:PROGESTERONE
CAS:57-83-0
RTECS #:TW0175000
= Wt:100.

=====================  Hazards Identification  =====================

Routes of Entry: Inhalation:YES  Skin:YES  Ingestion:YES
Reports of Carcinogenicity:NTP:YES    IARC:YES	  OSHA:NO
Health Hazards Acute and Chronic:INHALATION: PROGESTERONE: ACUTE
    EXPOSURE - AIRBORNE PARTICLES OF SEX HORMONES MAY BE ABSORBED THRU
    INHALATION. EXCESS PROGESTAGENS IN WOMEN MAY CAUSE WEIGHT GAIN,
    ACNE, MASTALGIA, GYNECOMASTIA, RECURR ENT MONOLIAL VAGINITIS. OTHER
    SYMPTOMS MAY INCLUDE HEADACHE, NAUSEA, PHOTOSENSITIVITY, CHLOASMA,
    LOSS OF LIBIDIO, BREAKTHROUGH BLEEDING, HYPERTENSION, PORPHYRIA,
    CHOLESTATIC LIVER DAMAGE AND STERILITY . EXCESS PROGESTAGEN IN MEN
    MAY RESULT IN SOME OF GENERAL SYMPTOMS EXHIBITED BY WOMEN AND MAY
    ALSO INHIBIT SPERMATOGENESIS. FETAL EXPOSURE TO PROGESTERONE MAY
    RESULT IN CONGENITAL HEART DEFECTS, LIMB  (SIGNS & SYMPTOMS OF
    OVEREXPOSURE)
Explanation of Carcinogenicity:PROGESTERONE: IARC GROUP 2B, SUPPLEMENT
    7, PAGE 289, 1987. NTP 9TH REPORT ON CARCINOGENS, REASONABLY
    ANTICIPATED TO BE HUMAN CARCINOGENS LIST.
Effects of Overexposure:HEALTH HAZARDS ACUTE AND CHRONIC (CONT):
    REDUCTION DEFECTS, VIRILIZATION AND GENITAL ABNORMALITIES.	CHRONIC
    EXPOSURE - SEX HORMONES MAY ACCUMULATE AND REACH HIGH LEVELS EVEN
    IF ABSORPTION IS INTERMIT TENT. CONTINUOUS ADMINISTRATION OF
    PROGESTIN IN SUFFICIENT DOSE LEADS TO OVARIAN AND ENDOMETRIAL
    ATROPHY. VERY SMALL DOSES MAY ALTER THE STRUCTURE OF THE
    ENDOMETRIUM. PROLONGED OR REPEATED EXPOSURE IN  MEN MAY RESULT IN
    GYNECOMASTIA. REPRODUCTIVE EFFECTS HAVE BEEN REPORTED IN ANIMALS. 
    SKIN CONTACT: PROGESTERONE: ACUTE EXPOSURE - AIRBORNE PARTICLES OF
    SEX HORMONES MAY BE ABSORBED THROUGH INTACT SKI N. EXCESS
    PROGESTAGENS IN (SARA III)

=======================  First Aid Measures  =======================

First Aid:INHALATION: MOVE TO FRESH AIR IMMED. IF BREATHING STOPPED,
    GIVE ARTF RESP. KEEP VICTIM WARM & AT REST. TREAT
    SYMPTOMATICALLY/SUPPORTIVELY. GET MED ATTN IMMED. SKIN: REMOVE
    CONTAM CLOTHING/SHOES IMMED.  WASH AFFECTED AREA W/SOAP & WATER
    UNTIL NO EVIDENCE OF CHEMICAL REMAINS (15-20 MIN). GET MED ATTN
    IMMED. EYES: WASH WITH LARGE AMOUNTS WATER/NORMAL SALINE, LIFTING
    EYELIDS OCCAS. FOR APPROX 15-20 MIN . GET MED ATTN IMMED.
    INGESTION: TREAT SYMPTOMATICALLY/SUPPORTIVELY. IF VOMITING OCCURS,
    KEEP HEAD LOWER THAN HIPS TO PREVENT ASPIRATION. GET MEDICAL ATTN
    IMMEDIATELY. ANTIDOTE: NO SPECIFIC ANTIDOTE.  TREAT
    SYMPTOMATICALLY/SUPPORTIVELY.

=====================  Fire Fighting Measures  =====================

Extinguishing Media:DRY CHEMICAL, CARBON DIOXIDE, WATER SPRAY OR
    REGULAR FOAM (1990 EMERGENCY RESPONSE GUIDEBOOK, DOT P 5800.5). USE
    AGENTS (UNUSUAL FIRE/EXP HAZARD)
Fire Fighting Procedures:MOVE CONTAINER FROM FIRE AREA IF IT CAN BE
    DONE WITHOUT RISK. DO NOT SCATTER SPILLED MATERIAL WITH
    HIGH-PRESSURE WATER STREAMS. DIKE FIRE-CONTROL WATER FOR LATER
    DISPOSAL (1990 EMER RESP GUIDEBOOK, DO T P 5800.5, PG 31). USE
    NIOSH-APPROVED SCBA AND FULL PROTECTIVE EQUIPMENT .
Unusual Fire/Explosion Hazard:NEGLIGIBLE FIRE HAZARD WHEN EXPOSED TO
    HEAT OR FLAME.  AVOID BREATHING HAZARDOUS VAPORS, KEEP UPWIND. 
    EXTINGUISHING MEDIA (CONT): SUITABLE FOR TYPE OF SURROUNDING FIRE. 
    FOR LARGER FIRES, USE WATER S PRAY, FOG OR REGULAR FOAM (1990
    EMERGENCY RESPONSE GUIDEBOOK, DOT P 5800.5).

==================  Accidental Release Measures  ==================

Spill Release Procedures:WATER SPILL: THE CALIFORNIA SAFE DRINKING
    WATER AND TOXIC ENFORCEMENT ACT OF 1986 (PROPOSITION 65) PROHIBITS
    CONTAMINATING ANY KNOWN SOURCE OF DRINKING WATER WITH SUBSTANCES
    KNOWN TO CAUSE CANCER AND/ OR REPRODUCTIVE TOXICITY. OCCUPATIONAL
    SPILL: NO SPECIAL PRECAUTIONS INDICATED.

======================	Handling and Storage  ======================

Handling and Storage Precautions:OBSERVE ALL FEDERAL, STATE AND LOCAL
    REGULATIONS WHEN STORING OR DISPOSING OF THIS SUBSTANCE. FOR
    ASSISTANCE, CONTACT THE DISTRICT DIRECTOR OF THE ENVIRONMENTAL
    PROTECTION AGENCY.

=============  Exposure Controls/Personal Protection  =============

Respiratory Protection:THE FOLLOWING RESPIRATORS RECOMMENDED BASED ON
    INFO FOUND IN THE PHYSICAL DATA, TOXICITY AND HEALTH EFFECTS
    SECTIONS. THEY ARE RANKED IN ORDER FROM MINIMUM TO MAXIMUM RESP
    PROTECTION. SPECIFIC RESPIRA TOR SELECTED MUST BE BASED ON CONTAM
    LEVELS FOUND IN WORKPLACE, SPECIFIC OPERATION, NOT EXCEED WORKING
    LIMITS OF RESP & BE APPROVED (WORK / HYGIENE PRACTICES)
Ventilation:PROVIDE LOCAL EXHAUST OR PROCESS ENCLOSURE VENTILATION
    SYSTEM.
Protective Gloves:WEAR APPROPRIATE PROTECTIVE GLOVES TO PREVENT CONTACT
    WITH THIS SUSTANCE.
Eye Protection:WEAR SPLASH-PROOF OR DUST-RESISTANT SAFETY GOGGLES (ANSI
    APPROVED - ).
Other Protective Equipment:EYEWASH AND DELUGE SHOWER MEETING ANSI
    DESIGN CRITERIA . APPROPRIATE PROTECTIVE (IMPERVIOUS) CLOTHING AND
    EQUIPMENT TO PREVENT REPEATED/PROLONGED SKIN CONTACT WITH THIS
    SUBSTANCE.
Work Hygienic Practices:RESPIRATORY PROT (CONT): BY NIOSH. ANY TYPE 'C'
    SUPPLIED-AIR RESP WITH FULL FACEPIECE OPERATED IN PRESSURE-DEMAND /
    OTHER POSITIVE PRESSURE MODE OR WITH FULL FACEPIECE, HELMET OR HOOD
    (TRANSPORT INFO)
Supplemental Safety and Health
CHEMICAL FAMILY: STEROID.  MOLECULAR FORMULS: C21-H30-O2.  MOLECULAR
    WEIGHT: 314.51.  NFPA RATINGS (SCALE 0-4): HEALTH = 3, FIRE = 3,
    REACTIVITY = 0. EXPOSURE LIMITS: NO OCCUPATIONAL EXPOSURE LIMITS E
    STABLISHED BY OSHA, ACGIH OR NIOSH.  PHYSICAL/CHEMICAL PROPERTIES
    (CONT): SOLVENT SOLUBILITY: ALCOHOL, ACETONE, DIOXANE.

==================  Physical/Chemical Properties  ==================

Melt/Freeze Pt:=127.2C, 261.F
Spec Gravity:1.17 @ 23 C
Solubility in Water:PRACTICALLY INSOLUBLE.
Appearance and Odor:WHITE CRYSTALLINE POWDER, ODORLESS, LIGHT
    SENSITIVE.

=================  Stability and Reactivity Data  =================

Stability Indicator/Materials to Avoid:YES
STRONG OXIDIZERS: FIRE & EXPLOSION HAZARD.
Stability Condition to Avoid:STABLE UNDER NORMAL TEMPERATURES AND
    PRESSURES. CONDITIONS TO AVOID: NONE REPORTED.
Hazardous Decomposition Products:THERMAL DECOMPOSITION PRODUCTS MAY
    INCLUDE TOXIC OXIDES OF CARBON.
Conditions to Avoid Polymerization:HAZARDOUS POLYMERIZATION NOT BEEN
    REPORTED TO OCCUR UNDER NORMAL TEMPERATURES AND PRESSURES.

===================  Toxicological Information	===================

Toxicological Information:PROGESTERONE: TOXICITY DATA: 100 MG/KG
    INTRAVENOUS-MOUSE LDLO: 327 MG/KG. INTRAPERITONEAL-RAT LDLO:
    MUTAGENIC DATA (RTECS); REPRODUCTIVE EFFECTS DATA (RTECS);
    TUMORIGENIC DATA (RTECS). CARCINOGEN STAT US: ANTICIPATED HUMAN
    CARCINOGEN (NTP); HUMAN INADEQUATE EVIDENCE (IARC GROUP 2B FOR
    PROGESTINS); ANIMAL SUFFICIENT EVIDENCE (IARC). IN ABSENCE OF
    EPIDEMIOLOGICAL DATA, NO EVALUATION OF CARCINOGENICIT Y OF
    PROGESTERONE TO HUMANS CAN BE MADE. PROGESTERONE WAS TESTED BY
    SUBCUTANEOUS AND INTRAMUSCULAR INJECTION IN RATS, MICE, RABBITS AND
    DOGS AND SUCUTANEOUS IMPLANTATION IN MICE AND RATS. IT WAS TESTE D
    ALONE IN MICE AND (ECOLOGICAL INFO)

=====================  Ecological Information  =====================

Ecological:N/P.   TOXICOLOGICAL INFO (CONT): DOGS; IN RATS AND RABBITS
    IT WAS ALWAYS GIVEN IN COMBINATION WITH OTHER SEX HORMONES. WHEN
    GIVEN ALONE, IT INCREASED THE INCIDENCE OF OVARIAN, UTERINE AND
    MAMMARY TUM ORS IN MICE. NEONATAL TREATMENT WITH PROGESTERONE
    ENHANCED THE OCCURRENCE OF PRECANCEROUS AND CANCEROUS LESIONS OF
    THE GENITAL TRACT AND RESULTED IN INCREASED MAMMARY TUMORIGENESIS
    IN FEMALE RATS.  AC UTE TOXICITY LEVEL: INSUFFICIENT DATA.	TARGET
    EFFECTS: POISONING MAY AFFECT THE LIVER.

====================  Disposal Considerations  ====================

Waste Disposal Methods:OBSERVE ALL FEDERAL, STATE AND LOCAL REGULATIONS
    WHEN STORING OR DISPOSING OF THIS SUBSTANCE. FOR ASSISTANCE,
    CONTACT THE DISTRICT DIRECTOR OF THE ENVIRONMENTAL PROTECTION
    AGENCY.

===================  MSDS Transport Information  ===================

Transport Information:N/P.  WORK HYGIENE PRACTICES (CONT): OPERATED IN
    CONTINUOUS-FLOW MODE. ANY SELF-CONTAINED BREATHING APPARATUS WITH A
    FULL FACEPIECE OPERATED IN PRESS-DEMAND MODE OR OTHER POS PRESSURE
    MODE. FOR FIREFI GHTING & OTHER IMMED DANGEROUS TO LIFE OR HEALTH
    CONDITIONS: ANY SELF-CONTAINED BREATHING APP W/FULL FACEPIECE &
    OPERATED IN PRESSURE-DEMAND/OTHER POSITIVE-PRESSURE MODE. ANY
    SUPPLIED-AIR RESP W/FULL  FACEPIECE & OPERATED IN PRESSURE
    DEMAND/OTHER POSITIVE-PRESSURE MODE IN COMBINATION WITH AN
    AUXILIARY SELF-CONTAINED BREATHING APPARATUS OPERATED IN
    PRESSURE-DEMAND OR OTHER POSITIVE-PRESSURE MODE.

=====================  Regulatory Information  =====================

SARA Title III Information:N/P.   SIGNS & SYMPTOMS OF OVEREXP (CONT):
    WOMEN MAY CAUSE WEIGHT GAIN, ACNE, MASTALGIA, GYNECOMASTIA &
    RECURRENT MONOLIAL VAGINITIS. OTHER SYMPS MAY INCL HEADACHE,
    NAUSEA, PHOTOSENSITIVITY, CHLOASMA,  LOSS OF LIBIDO, BREAKTHROUGH
    BLEEDING, HYPERTENSION, PORPHYRIA, CHOLESTATIC LIVER DAMAGE &
    STERILITY. EXCESS PROGESTAGENS IN MEN MAY RESULT IN SOME GENERAL
    SYMPTOMS EXHIBITED BY WOMEN, & MAY ALSO INH IBIT SPERMATOGENISIS.
    FETAL EXPOSURE TO PROGESTERONE MAY RESULT IN COGENITAL HEAT
    DEFECTS, LIMB REDUCTION DEFECTS, VIRILIZATION & GENITAL ABNORM. 
    CHRONIC EXPOSURES - SEX HORMONES MAY ACCUM & REACH HI GH LEVELS
    EVEN IF ABSORPTION (FED REGS)
Federal Regulatory Information:CERCLA RATINGS: (SCALE 0-3): HEALTH-3,
    FIRE-0, REACTIVITY-0, PERSISTENCE-3.  SARA III (CONT): IS
    INTERMITTENT. CONTINUOUS ADMIN OF A PROGESTIN IN SUFFICIENT DOSES
    LEADS TO OVARIAN & ENDOMETRIAL ATROPH Y. VERY SMALL DOSES MAY ALTER
    THE STRUCTURE OF THE ENDOMETRIUM. REPROD EFFECTS HAVE BEEN REPORTED
    IN ANIMALS. EYE CONTACT: PROGESTERONE: ACUTE EXPOSURE - NO DATA
    AVAIL. CONTACT WITH THE DUST OR POWDER  MAY BE IRRITATING.	CHRONIC
    EXPOSURE - NO DATA AVAIL. INGESTION: PROGESTERONE: ACUTE EXPOSURE -
    EXC ESS PROGESTAGENS IN WOMEN MAY CAUSE WEIGHT GAIN, ACNE,
    MASTALGIA, GYNECOMASTIA & RECURRENT MONOLIAL VAGINITIS. OTHER
    SYMPTOMS  (STATE REGS)
State Regulatory Information:SUBJECT TO CALIFORNIA PROPOSITION 65
    CANCER AND/OR REPRODUCTIVE TOXICITY  WARNING AND RELEASE
    REQUIREMENTS-(JANUARY 1, 1988).   FED REGS (CONT): MAY INCL
    HEADACHE, NAUSEA, PHOTOSENSITIVITY, CHLOASMA,  LOSS OF LIBIDO,
    BREAKTHROUGH BLEEDING, HYPERTENSION, PORPHYRIA, CHOLESTATIC LIVER
    DAMAGE & STERILITY. EXCESS PROGESTAGENS IN MEN MAY RESULT IN SOME
    GENERAL SYMPS EXHIBITED BY WOMEN, & MAY ALSO INHIBIT 
    SPERMATOGENISIS. FETAL EXPOSURE TO PROGESTERONE MAY RESULT IN
    COGENITAL HEART DEFECTS, LIMB REDUCTI ON DEFECTS, VIRILIZATION &
    GENITAL ABNORM. CONTINUOUS ADMIN OF A PROGESTIN IN SUFF DOSE LEADS
    TO OVARIAN & ENDOMETRIAL ATROPHY. (OTHER INFO)

=======================  Other Information  =======================

 Disclaimer (provided with this information by the compiling agencies):
 This information is formulated for use by elements of the Department
 of Defense.  The United States of America in no manner whatsoever,
 expressly or implied, warrants this information to be accurate and
 disclaims all liability for its use.  Any person utilizing this
 document should seek competent professional advice to verify and
 assume responsibility for the suitability of this information to their
 particular situation.'